Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,834
  • Shares Outstanding, K 9,047
  • Annual Sales, $ 0 K
  • Annual Income, $ 140 K
  • EBIT $ -96 M
  • EBITDA $ -89 M
  • 60-Month Beta 0.19
  • Price/Sales 413.81
  • Price/Cash Flow N/A
  • Price/Book 2.99

Options Overview Details

View History
  • Implied Volatility 188.40% ( +11.98%)
  • Historical Volatility 65.50%
  • IV Percentile 75%
  • IV Rank 21.81%
  • IV High 554.55% on 04/15/25
  • IV Low 86.26% on 08/25/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 31
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 13,304
  • Open Int (30-Day) 14,006

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.37
  • Number of Estimates 2
  • High Estimate -2.34
  • Low Estimate -2.39
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.48 +34.65%
on 11/05/25
20.85 -19.42%
on 10/16/25
-2.43 (-12.64%)
since 10/13/25
3-Month
12.48 +34.65%
on 11/05/25
24.67 -31.89%
on 09/08/25
+0.83 (+5.20%)
since 08/13/25
52-Week
6.53 +157.27%
on 05/15/25
24.67 -31.89%
on 09/08/25
+5.00 (+42.32%)
since 11/13/24

Most Recent Stories

More News
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant...

MCRB : 16.77 (+4.72%)
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...

MCRB : 16.77 (+4.72%)
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria...

MCRB : 16.77 (+4.72%)
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from...

MCRB : 16.77 (+4.72%)
Seres Therapeutics Cuts Costs to Extend Cash Runway

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Seres Therapeutics...

MCRB : 16.77 (+4.72%)
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell...

MCRB : 16.77 (+4.72%)
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright...

MCRB : 16.77 (+4.72%)
Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 16.77 (+4.72%)
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT)...

MCRB : 16.77 (+4.72%)
SANA : 3.66 (-9.85%)
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...

MCRB : 16.77 (+4.72%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 18.04
2nd Resistance Point 17.17
1st Resistance Point 16.59
Last Price 16.77
1st Support Level 15.14
2nd Support Level 14.27
3rd Support Level 13.69

See More

52-Week High 24.67
Fibonacci 61.8% 17.74
Last Price 16.77
Fibonacci 50% 15.60
Fibonacci 38.2% 13.46
52-Week Low 6.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar